Neoplasms

Skin and Connective Tissue Diseases

All Conditions

Breast Neoplasms

Breast Diseases

Skin Diseases

Antineoplastic Agents

All Drugs and Chemicals

Antirheumatic Agents

Anti-Infective Agents

Paclitaxel

Cyclophosphamide

Doxorubicin

Liposomal doxorubicin

Albumin-Bound Paclitaxel

Tubulin Modulators

Antimitotic Agents

Immunosuppressive Agents

Immunologic Factors

Antineoplastic Agents, Alkylating

Alkylating Agents

Anti-Bacterial Agents

Antibiotics, Antitubercular

Enzyme Inhibitors

Women with invasive breast cancer; clinical stage III, condition to receive neoadjuvant chemotherapy based in doxorubicin/ cyclophosphamide and paclitaxel followed by surgery (mastectomy and axillary lymph node dissection)

doxorubicin

cyclophosphamide

4 cycles T: paclitaxel 175mg/m2 after 4 AC

paclitaxel

The surgery will be performed 30 days after the chemotherapy. The correlation between clinical, radiologic and pathologic response will be reported.

The oncoplastic surgery rate will be reported

Surgery

Maria Aparecida A Koike Folgueira, MD, PhD

The purpose of this study is to analyze gene expression signature and immunohistochemical markers associated with clinical and pathological response to neoadjuvant chemotherapy in locally advanced breast cancer.

Locally advanced breast cancer is a common condition in development countries. Neoadjuvant chemotherapy gives the opportunity to identify genetic signatures associated with objective clinical and pathological complete responses.

Patients will receive doxorubicin/cyclophosphamide with paclitaxel. Tumor samples collected before and after chemotherapy will be analyzed.

Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer

Gene Expression Signature and Immunohistochemical Markers Associated With Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer

Clinical and radiological examinations to be performed before chemotherapy, after the 4 cycle of AC and before surgery.

Pathologic evaluation to be performed 30 days after the last cycle of chemotherapy, i.g. after surgery.

tumor concordance measurement among pre-operative physical examination (PE), mammography (MG), ultrasound (US), breast MRI and post-operative pathologic measurement concordance with PE, MG, US and MRI

The use and security of oncoplastic surgery after neoadjuvant chemotherapy

Pathologic complete response after neoadjuvant chemotherapy

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer	NCT00820690	Breast Cancer	doxorubicin cyclophosphamid... paclitaxel Surgery	18 Years - 70 Years	Barretos Cancer Hospital
Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer	NCT00820690	Breast Cancer	doxorubicin cyclophosphamid... paclitaxel Surgery	18 Years - 70 Years	Barretos Cancer Hospital

Spots Global Cancer Trial Database for correlation analysis